Nutra Pharma(OTC) NPHC

Nutra Pharma makes pain relief products for people and animals. Its main products help manage chronic pain without narcotics. The company also develops treatments for neurological and autoimmune diseases.

Pain Relief, Pets, and More: What’s on the Shelf?

• Nyloxin Products: Over-the-counter pain relievers for chronic pain, available as gels and sprays; target adults with back pain, migraines, and arthritis. (67-68% of revenue via related party sales in H1 2023)
• Nyloxin Military Strength: Higher-concentration pain relief for US military and veterans; used for severe pain management.
• Pet Pain-Away: Non-narcotic pain relief for chronic pain in dogs and cats; sold over the counter.
• Luxury Feet: Pain and anti-inflammatory product for foot discomfort, especially for women wearing high heels.
• Equine Pain-Away: Topical pain relief for horses; addresses joint and muscle pain in equine care.
• Pipeline Drugs: RPI-78M and RPI-MN in development for neurological, autoimmune, and viral diseases; not yet commercialized.

Growth Spurts and Side Quests

• Launched Luxury Feet in 2021 and Equine Pain-Away in 2019, diversifying product lines.
• Entered contract manufacturing for Cell Defender in 2021, supplying a third-party distributor.
• Signed research services agreement with StemSation in July 2024 (terminated March 2025).
• Pursued international registration for Nyloxin products, but progress delayed by funding limits.

What Makes Nutra Pharma Stand Out?

Nutra Pharma focuses on non-narcotic pain relief using homeopathic and biologic ingredients, such as cobra venom. Its products are sold through online platforms and select physical locations, reaching both consumers and professionals. The company’s pipeline includes drug candidates with orphan drug status, which can offer regulatory advantages.

Five Things You Need to Know

• Revenue was $109,204 in Q3 2022, up 466.8% from Q3 2021.
• Gross profit margin reached 51.3% in Q2 2023, up from 32.7% prior year.
• Related party sales made up 67-68% of total revenue in H1 2023.
• Net loss was $(279,246) in Q2 2023, improved from $(645,800) prior year.
• No cash on hand and a working capital deficit of $13.3 million as of June 2023.

Bottom Line

Nutra Pharma has diversified its pain relief offerings and expanded into animal health and drug development. The company faces significant financial and operational challenges but continues to pursue new markets and products.